-+ 0.00%
-+ 0.00%
-+ 0.00%

Enanta doses first participant in Phase 1 trial of urticaria drug EDP-978

PUBT·04/13/2026 11:01:32
Listen to the news
Enanta doses first participant in Phase 1 trial of urticaria drug EDP-978
  • Enanta began first-in-human Phase 1 trial of EDP-978, an oral once-daily KIT inhibitor being developed for urticaria.
  • Study will assess safety and drug behavior in healthy volunteers, with biomarker readouts intended to indicate biological activity.
  • Topline results have not been presented; Enanta expects to report Phase 1 data in Q4 2026.
  • Program positions Enanta to advance an oral option for patients who remain poorly controlled on existing therapies, supporting its push into immunology beyond antivirals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604130700BIZWIRE_USPR_____20260413_BW254076) on April 13, 2026, and is solely responsible for the information contained therein.